Strong 5-aminolevulinic acid-induced fluorescence is a novel intraoperative marker for representative tissue samples in stereotactic brain tumor biopsies

Neurosurgical Review

Volumn 35, Issue 3, 2012, Pages 381-391

  Widhalm, Georg ^a,b   Minchev, Georgi ^a   Woehrer, Adelheid ^a,b   Preusser, Matthias ^a   Kiesel, Barbara ^a,b   Furtner, Julia ^a   Mert, Aygül ^a   Ieva, Antonio Di ^a   Tomanek, Boguslaw ^c   Prayer, Daniela ^a   Marosi, Christine ^a   Hainfellner, Johannes A ^a,b   Knosp, Engelbert ^a   Wolfsberger, Stefan ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

5 Aminolevulinic acid; Diagnostic accuracy; Diagnostic yield; Representative sample; Stereotactic biopsy. Strong fluorescence

Indexed keywords

AMINOLEVULINIC ACID;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ASTROCYTOMA; BRAIN BIOPSY; BRAIN METASTASIS; BRAIN TUMOR; CLINICAL ARTICLE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; FEMALE; FLUORESCENCE; FRAMELESS STEREOTACTIC PROCEDURE; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRAOPERATIVE PERIOD; MALE; MICROSCOPE; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; STEREOTACTIC BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; BIOPSY; BRAIN NEOPLASMS; FEMALE; FLUORESCENCE; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROIMAGING; NEUROSURGICAL PROCEDURES; PHOTOSENSITIZING AGENTS; YOUNG ADULT;

EID: 84862888451     PISSN: 03445607     EISSN: 14372320     Source Type: Journal    
DOI: 10.1007/s10143-012-0374-5     Document Type: Review

References (38)

1. Aker FV, Hakan T, Karadereler S, Erkan M (2005) Accuracy and diagnostic yield of stereotactic biopsy in the diagnosis of brain masses: comparison of results of biopsy and resected surgical specimens. Neuropathology 25(3):207-213.
2. Calisaneller T, Ozdemir O, Ozger O, Ozen O, Kiyici H, Caner H, Altinors N (2008) The accuracy and diagnostic yield of computerized tomography guided stereotactic biopsy in brain lesions. Turk Neurosurg 18(1):17-22
3. Dammers R, Haitsma IK, Schouten JW, Kros JM, Avezaat CJ, Vincent AJ (2008) Safety and efficacy of frameless and framebased intracranial biopsy techniques. Acta Neurochir (Wien) 150 (1):23-29
4. Dammers R, Schouten JW, Haitsma IK, Vincent AJ, Kros JM, Dirven CM (2010) Towards improving the safety and diagnostic yield of stereotactic biopsy in a single centre. Acta Neurochir (Wien) 152(11):1915-1921
5. Dickerman RD, Mittler MA, Morgan JT (2005) Stereotactic brain biopsies and operative complications: technique to further decrease risks. Acta Neurochir (Wien) 147(8):911-912
6. Dorward NL, Paleologos TS, Alberti O, Thomas DG (2002) The advantages of frameless stereotactic biopsy over frame-based biopsy. Br J Neurosurg 16(2):110-118
7. Eljamel MS (2009) Which intracranial lesions would be suitable for 5-aminolevulenic acid-induced fluorescence-guided identification, localization, or resection? A prospective study of 114 consecutive intracranial lesions. Clin Neurosurg 56:93-97
8. Field M, Witham TF, Flickinger JC, Kondziolka D, Lunsford LD (2001) Comprehensive assessment of hemorrhage risks and outcomes after stereotactic brain biopsy. J Neurosurg 94(4):545-551
9. Gralla J, Nimsky C, Buchfelder M, Fahlbusch R, Ganslandt O (2003) Frameless stereotactic brain biopsy procedures using the Stealth Station: indications, accuracy and results. Zentralbl Neurochir 64(4):166-170
10. Grossman R, Sadetzki S, Spiegelmann R, Ram Z (2005) Haemorrhagic complications and the incidence of asymptomatic bleeding associated with stereotactic brain biopsies. Acta Neurochir (Wien) 147(6):627-631
11. Hall WA (1998) The safety and efficacy of stereotactic biopsy for intracranial lesions. Cancer 82(9):1749-1755
12. HallWA, Truwit CL (2008) IntraoperativeMR-guided neurosurgery. J Magn Reson Imaging 27(2):368-375
13. Hefti M, von Campe G, Moschopulos M, Siegner A, Looser H, Landolt H (2008) 5-aminolevulinic acid induced protoporphyrin IX fluorescence in high-grade glioma surgery: A one-year experience at a single institution. Swiss Med Wkly 138(11-12):180-185
14. Heper AO, Erden E, Savas A, Ceyhan K, Erden I, Akyar S, Kanpolat Y (2005) An analysis of stereotactic biopsy of brain tumors and nonneoplastic lesions: A prospective clinicopathologic study. Surg Neurol 64(SUPPL. 2):S82-88
15. Hermann EJ, Hattingen E, Krauss JK, Marquardt G, Pilatus U, Franz K, Setzer M, Gasser T, Tews DS, Zanella FE, Seifert V, Lanfermann H (2008) Stereotactic biopsy in gliomas guided by 3-tesla 1H-chemical-shift imaging of choline. Stereotact Funct Neurosurg 86(5):300-307
16. Jackson RJ, Fuller GN, Abi-Said D, Lang FF, Gokaslan ZL, Shi WM, Wildrick DM, Sawaya R (2001) Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol 3 (3):193-200
17. Jain D, Sharma MC, Sarkar C, Deb P, Gupta D, Mahapatra AK (2006) Correlation of diagnostic yield of stereotactic brain biopsy with number of biopsy bits and site of the lesion. Brain Tumor Pathol 23(2):71-75
18. Kelly PJ (1991) Tumor stereotaxis. WB Saunders, Philadelphia
19. Kondziolka D, Firlik AD, Lunsford LD (1998) Complications of stereotactic brain surgery. Neurol Clin 16(1):35-54
20. Krieger MD, Chandrasoma PT, Zee CS, Apuzzo ML (1998) Role of stereotactic biopsy in the diagnosis and management of brain tumors. Semin Surg Oncol 14(1):13-25
21. Kulkarni AV, Guha A, Lozano A, Bernstein M (1998) Incidence of silent hemorrhage and delayed deterioration after stereotactic brain biopsy. J Neurosurg 89(1):31-35
22. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO classification of the central nervous system. IARC, Lyon
23. Lunsford LD, Niranjan A, Khan AA, Kondziolka D (2008) Establishing a benchmark for complications using frame-based stereotactic surgery. Stereotact Funct Neurosurg 86(5):278-287
24. Muragaki Y, Chernov M, Maruyama T, Ochiai T, Taira T, Kubo O, Nakamura R, Iseki H, Hori T, Takakura K (2008) Low-grade glioma on stereotactic biopsy: how often is the diagnosis accurate? Minim Invasive Neurosurg 51(5):275-279
25. Pirotte B, Goldman S, David P,Wikler D, Damhaut P, Vandesteene A, Salmon L, Brotchi J, Levivier M (1997) Stereotactic brain biopsy guided by positron emission tomography (PET) with [F-18]fluorodeoxyglucose and [C-11]methionine. Acta Neurochir SUPPL. 68:133-138
26. Pirotte B, Goldman S, Massager N, David P, Wikler D, Lipszyc M, Salmon I, Brotchi J, Levivier M (2004) Combined use of 18Ffluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. J Neurosurg 101 (3):476-483
27. Potzi C, Becherer A, Marosi C, Karanikas G, Szabo M, Dudczak R, Kletter K, Asenbaum S (2007) [11C] methionine and [18F] fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme. J Neurooncol 84(3):305-314
28. Sawin PD, Hitchon PW, Follett KA, Torner JC (1998) Computed imaging-assisted stereotactic brain biopsy: A risk analysis of 225 consecutive cases. Surg Neurol 49(6):640-649
29. Shooman D, Belli A, Grundy PL (2010) Image-guided frameless stereotactic biopsy without intraoperative neuropathological examination. J Neurosurg 113(2):170-178
30. Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ (2000) Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: A prospective study in 52 consecutive patients. J Neurosurg 93 (6):1003-1013..
31. StummerW, Pichlmeier U, Meinel T,Wiestler OD, Zanella F, Reulen HJ (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial. Lancet Oncol 7(5):392-401
32. Stummer W, Stepp H, Moller G, Ehrhardt A, Leonhard M, Reulen HJ (1998) Technical principles for protoporphyrin-IX-fluorescence guided microsurgical resection of malignant glioma tissue. Acta Neurochir (Wien) 140(10):995-1000
33. Tilgner J, Herr M, Ostertag C, Volk B (2005) Validation of intraoperative diagnoses using smear preparations from stereotactic brain biopsies: intraoperative versus final diagnosis-influence of clinical factors. Neurosurgery 56(2):257-265, discussion 257-265
34. Widhalm G, Krssak M, Minchev G,Wohrer A, Traub-Weidinger T, Czech T, Asenbaum S, Marosi C, Knosp E, Hainfellner JA, Prayer D, Wolfsberger S (2011) Value of 1H-magnetic resonance spectroscopy chemical shift imaging for detection of anaplastic foci in diffusely infiltrating gliomas with non-significant contrastenhancement. J Neurol Neurosurg Psychiatry 82(5):512-20
35. Widhalm G, Wolfsberger S, Minchev G, Woehrer A, Krssak M, Czech T, Prayer D, Asenbaum S, Hainfellner JA, Knosp E (2010) 5-Aminolevulinic acid is a promising marker for detection of anaplastic foci in diffusely infiltrating gliomas with nonsignificant contrast enhancement. Cancer 116(6):1545-1552
36. Wolfsberger S, Rossler K, Regatschnig R, Ungersbock K (2002) Anatomical landmarks for image registration in frameless stereotactic neuronavigation. Neurosurg Rev 25(1-2):68-72
37. Woodworth G, McGirt MJ, Samdani A, Garonzik I, Olivi A, Weingart JD (2005) Accuracy of frameless and frame-based image-guided stereotactic brain biopsy in the diagnosis of glioma: comparison of biopsy and open resection specimen. Neurol Res 27 (4):358-362
38. Zoeller GK, Benveniste RJ, Landy H, Morcos JJ, Jagid J (2009) Outcomes and management strategies after nondiagnostic stereotactic biopsies of brain lesions. Stereotact Funct Neurosurg 87 (3):174-181